Finance

Lists
RCKT:NASDAQ
Rocket Pharmaceuticals Inc
၃.၇၀ US$
-၀.၆၇%
(-၀.၀၂၅) 1D
စက် ၁, GMT-၄ ၁၀:၂၉:၁၅  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCKT...
Open
၃.၇၂ US$
High
၃.၇၅ US$
Low
၃.၆၇ US$
Mkt. cap
၄၀.၅၆ ကုဋေ
Avg. vol.
၁.၅၁ သန်း
Volume
၂.၁၂ သိန်း
52-wk high
၅.၄၅ US$
52-wk low
၂.၅၃ US$
EPS
-၀.၁၈ US$
Beta
၀.၄၇
Shares outstanding
၁၀.၉၈ ကုဋေ
No. of employees
၂၀၂
Open
၃.၇၂ US$
High
၃.၇၅ US$
Low
၃.၆၇ US$
Mkt. cap
၄၀.၅၆ ကုဋေ
Avg. vol.
၁.၅၁ သန်း
Volume
၂.၁၂ သိန်း
52-wk high
၅.၄၅ US$
52-wk low
၂.၅၃ US$
EPS
-၀.၁၈ US$
Beta
၀.၄၇
Shares outstanding
၁၀.၉၈ ကုဋေ
No. of employees
၂၀၂
News stories
From web sources and news partners
GuruFocus
GuruFocus
·
ပြီးခဲ့သည့် ၅၉ မိနစ်
RCKT Maintained by Chardan Capital -- Price Target Stays at $11.
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၁ နာရီ
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating
About Rocket Pharmaceuticals Inc
CEO-
Employees၂၀၂
Founded၁၉၉၉
HeadquartersCranbury, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Analyst ratings
Based on 9 analysts giving stock ratings to RCKT in the past 3 months
Buy
Buy
6
Hold
3
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RCKT in the last 3 months.
Highest
Current ၃.၇၀ US$
၁၅.၀၀ US$ (+၃၀၅.၉၅%)
Average
၁၁.၁၄ US$ (+၂၀၁.၄၉%)
Lowest
၅.၀၀ US$ (+၃၅.၃၂%)
Analyst
Recommendation
Action
Price target
Projected
Date
Keay Nakae
Chardan Capital
Buy
Maintained
၁၁.၀၀ US$
+၁၉၇.၇%
09/01/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
၁၀.၀၀ US$
+၁၇၀.၆%
08/12/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
၅.၀၀ US$
+၃၅.၃%
08/12/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
၁၅.၀၀ US$
+၃၀၆%
08/10/2026
Yun Zhong
Wedbush
Buy
Reiterated
၁၅.၀၀ US$
+၃၀၆%
08/11/2026
Gil Blum
Needham
Hold
Reiterated
-
-
08/11/2026
Tara Bancroft
TD Cowen
Hold
Maintained
-
-
08/10/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
၁၂.၀၀ US$
+၂၂၄.၈%
08/10/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
၁၀.၀၀ US$
+၁၇၀.၆%
08/03/2026
Geulah Livshits
Chardan Capital
Buy
Reiterated
၁၁.၀၀ US$
+၁၉၇.၇%
05/10/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
04/02/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
၁၁.၀၀ US$
+၁၉၇.၇%
03/27/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
၃.၀၀ US$
-၁၈.၈%
03/27/2026
Unknown Analyst
Canaccord Genuity
Buy
Maintained
၁၀.၀၀ US$
+၁၇၀.၆%
03/02/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၃.၄၁ ကုဋေ
၂.၉၃ ကုဋေ
၃.၁၅ ကုဋေ
၂.၉၅ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၈၄ ကုဋေ
၁.၄၇ ကုဋေ
၁.၇၁ ကုဋေ
၁.၇၄ ကုဋေ
Operating expense
၅.၂၄ ကုဋေ
၄.၄၀ ကုဋေ
၄.၈၅ ကုဋေ
၄.၆၉ ကုဋေ
Total operating expenses
၅.၂၄ ကုဋေ
၄.၄၀ ကုဋေ
၄.၈၅ ကုဋေ
၄.၆၉ ကုဋေ
Operating income
-၅.၂၄ ကုဋေ
-၄.၄၀ ကုဋေ
-၄.၈၅ ကုဋေ
-၄.၆၉ ကုဋေ
Other non operating income
-
-
-
-
EBT including unusual items
-၅.၀၃ ကုဋေ
-၄.၂၅ ကုဋေ
-၄.၇၆ ကုဋေ
၁၃.၁၈ ကုဋေ
EBT excluding unusual items
-၅.၂၂ ကုဋေ
-၄.၃၈ ကုဋေ
-၄.၈၈ ကုဋေ
-၄.၇၀ ကုဋေ
Income tax expense
-
-
-
၈.၆၂ သန်း
Effective tax rate
-
-
-
၆.၅၄%
Other operating expenses
-
-
-
-
Net income
-၅.၀၃ ကုဋေ
-၄.၂၅ ကုဋေ
-၄.၇၆ ကုဋေ
၁၂.၃၂ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၄၅
-၀.၃၈
-၀.၄၂
-၀.၃၈
Interest and investment income
၇.၀၉ သိန်း
၆.၉၀ သိန်း
၁.၆၁ သိန်း
၃.၄၇ သိန်း
Interest expense
-၄.၇၃ သိန်း
-၄.၇၃ သိန်း
-၄.၇၃ သိန်း
-၄.၇၃ သိန်း
Net interest expenses
၂.၃၆ သိန်း
၂.၁၇ သိန်း
-၃.၁၂ သိန်း
-၁.၂၆ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၉၂ ကုဋေ
-၄.၁၈ ကုဋေ
-၄.၆၄ ကုဋေ
-၄.၄၈ ကုဋေ
Gain or loss from assets sale
-
-
-
-၁၇.၈၂ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google အက်ပ်များ